Denali Therapeutics - DNLI Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $41.22
Forecasted Upside: 167.16%
Number of Analysts: 8
Breakdown:
0 Sell Ratings
0 Hold Ratings
8 Buy Ratings
0 Strong Buy Ratings

^$15.43 As of 04/26/2024 01:00 AM ET

▲ +0.47 (3.14%)

1 month | 3 months | 12 months

Get New Denali Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for DNLI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DNLI

^$41.22

▲ +167.16% Upside Potential

This price target is based on 8 analysts offering 12 month price targets for Denali Therapeutics in the last 3 months. The average price target is $41.22, with a high forecast of $95.00 and a low forecast of $28.00. The average price target represents a 167.16% upside from the last price of $15.43.

Current Consensus is Buy

The current consensus among 8 polled investment analysts is to buy stock in Denali Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
8 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/3/2022

0 strong buy ratings
8 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/1/2023

0 strong buy ratings
8 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/2/2023

0 strong buy ratings
8 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/31/2023

0 strong buy ratings
8 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

10/29/2023

0 strong buy ratings
8 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/27/2024

0 strong buy ratings
8 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/27/2024

0 strong buy ratings
8 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/26/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/9/2024	UBS Group	Lower Target	Buy ➝ Buy	$70.00 ➝ $32.00	Low
2/29/2024	The Goldman Sachs Group	Lower Target	Buy ➝ Buy	$73.00 ➝ $50.00	Low
2/28/2024	HC Wainwright	Lower Target	Buy ➝ Buy	$105.00 ➝ $95.00	Low
2/28/2024	Wedbush	Reiterated Rating	Outperform ➝ Outperform	$31.00	Low
2/22/2024	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$105.00	Low
12/13/2023	Citigroup	Initiated Coverage	Buy	$32.00	Low
11/20/2023	JPMorgan Chase & Co.	Reiterated Rating	Overweight	$28.00	Low
11/8/2023	Wedbush	Reiterated Rating	Outperform ➝ Outperform	$31.00	Low
10/24/2023	Cantor Fitzgerald	Reiterated Rating	Overweight	$85.00 ➝ $35.00	Low
9/6/2023	B. Riley	Initiated Coverage	Buy	$38.00	Low
8/31/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$85.00	Low
8/31/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$105.00	Low
8/22/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$85.00	Low
8/10/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$85.00	Low
8/9/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$105.00	Low
8/9/2023	Wedbush	Lower Target	Outperform ➝ Outperform	$37.00 ➝ $31.00	Low
5/9/2023	Stifel Nicolaus	Lower Target		$30.00	Low
4/12/2023	Morgan Stanley	Boost Target	Overweight	$61.00 ➝ $63.00	Low
3/2/2023	Stifel Nicolaus	Lower Target		$36.00 ➝ $32.00	Low
3/2/2023	Oppenheimer	Lower Target	Outperform	$85.00 ➝ $70.00	Low
3/1/2023	Morgan Stanley	Lower Target	Overweight	$65.00 ➝ $61.00	Low
2/28/2023	Evercore ISI	Lower Target	Outperform	$80.00 ➝ $50.00	Low
2/28/2023	Wedbush	Lower Target	Outperform	$46.00 ➝ $38.00	Low
2/23/2023	HC Wainwright	Reiterated Rating	Buy	$105.00	Low
1/30/2023	SVB Leerink	Reiterated Rating	Outperform	$50.00	Low
1/30/2023	SVB Securities	Initiated Coverage	Outperform	$50.00	Low
1/25/2023	Morgan Stanley	Boost Target	Overweight	$60.00 ➝ $65.00	Low
12/5/2022	Cowen	Initiated Coverage	Outperform		Low
12/5/2022	Cowen	Initiated Coverage	Outperform		Low
11/8/2022	Morgan Stanley	Lower Target	Overweight	$67.00 ➝ $60.00	Low
11/2/2022	BTIG Research	Upgrade	Neutral ➝ Buy	$38.00	Low
11/2/2022	Bank of America	Initiated Coverage	Buy	$40.00	N/A
6/23/2022	Berenberg Bank	Initiated Coverage	Buy	$39.00	Low
5/24/2022	The Goldman Sachs Group	Lower Target	Buy	$99.00 ➝ $82.00	Low
5/6/2022	Wedbush	Lower Target		$62.00 ➝ $48.00	High
3/7/2022	The Goldman Sachs Group	Lower Target	Buy ➝ Buy	$114.00 ➝ $98.00	High
3/1/2022	Wedbush	Reiterated Rating	Outperform		Medium
1/6/2022	Morgan Stanley	Lower Target	Overweight	$99.00 ➝ $91.00	Low
11/5/2021	Evercore ISI	Boost Target	Outperform	$70.00 ➝ $111.00	High
9/20/2021	Oppenheimer	Initiated Coverage	Outperform	$85.00	High
9/1/2021	Sumitomo Mitsui Financial Group	Initiated Coverage	Outperform	$78.00	High
8/16/2021	Morgan Stanley	Lower Target	Overweight	$100.00 ➝ $99.00	Medium
7/26/2021	HC Wainwright	Reiterated Rating	Buy	$95.00 ➝ $105.00	High
7/15/2021	HC Wainwright	Reiterated Rating	Buy	$95.00	Medium
5/18/2021	UBS Group	Initiated Coverage	Buy	$70.00	High
3/4/2021	HC Wainwright	Boost Target	Buy	$80.00 ➝ $95.00	High
2/26/2021	HC Wainwright	Reiterated Rating	Buy	$80.00 ➝ $95.00	High
2/10/2021	Cantor Fitzgerald	Upgrade	Neutral ➝ Overweight	$105.00	Low
1/8/2021	JPMorgan Chase & Co.	Initiated Coverage	Positive		Medium
12/16/2020	Morgan Stanley	Boost Target	Overweight	$75.00 ➝ $100.00	High
11/11/2020	JPMorgan Chase & Co.	Boost Target	Positive ➝ Overweight	$45.00 ➝ $65.00	High
11/11/2020	Morgan Stanley	Boost Target	Overweight	$45.00 ➝ $75.00	High
11/10/2020	The Goldman Sachs Group	Boost Target	Positive ➝ Buy	$61.00 ➝ $81.00	Low
11/6/2020	HC Wainwright	Boost Target	Buy	$45.00 ➝ $65.00	Medium
10/16/2020	Wedbush	Boost Target	Positive ➝ Outperform	$39.00 ➝ $50.00	High
10/16/2020	BTIG Research	Downgrade	Buy ➝ Neutral		High
9/14/2020	JPMorgan Chase & Co.	Initiated Coverage	Overweight	$35.00	High
8/24/2020	Morgan Stanley	Boost Target	Overweight	$28.00 ➝ $45.00	Medium
8/20/2020	HC Wainwright	Reiterated Rating	Buy	$28.00 ➝ $45.00	Medium
8/10/2020	Wedbush	Reiterated Rating	Outperform		Medium
5/13/2020	Nomura	Reiterated Rating	Buy	$35.00	Low
4/15/2020	Morgan Stanley	Lower Target	Overweight	$30.00 ➝ $28.00	High
3/18/2020	Cantor Fitzgerald	Reiterated Rating	Neutral		Medium
3/13/2020	Evercore ISI	Upgrade	In-Line ➝ Outperform	$20.00	High
3/9/2020	Nomura Securities	Reiterated Rating	Buy	$35.00	Low
2/28/2020	Wedbush	Upgrade	Neutral ➝ Outperform	$24.00	Low
2/24/2020	Jefferies Financial Group	Initiated Coverage	Buy	$35.00	High
2/18/2020	Stifel Nicolaus	Initiated Coverage	Hold	$26.00	Low
1/26/2020	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$20.00 ➝ $37.00	High
12/20/2019	HC Wainwright	Reiterated Rating	Buy	$28.00	Medium
9/25/2019	Wedbush	Initiated Coverage	Neutral	$19.00 ➝ $19.00	High
9/13/2019	Nomura Securities	Initiated Coverage	Buy	$35.00	High
8/9/2019	Morgan Stanley	Set Target	Buy	$32.00	Low
8/9/2019	BTIG Research	Initiated Coverage	Buy ➝ Buy	$30.00	High
8/8/2019	HC Wainwright	Reiterated Rating	Buy		Medium
7/15/2019	HC Wainwright	Set Target	Buy	$28.00	High
6/26/2019	HC Wainwright	Initiated Coverage	Buy ➝ Buy	$28.00	Medium

(Data available from 4/26/2019 forward)

News Sentiment Rating

0.96 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

4 very positive mentions
3 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

9/29/2023

1 very positive mentions
2 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

10/29/2023

0 very positive mentions
10 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

11/28/2023

3 very positive mentions
8 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

12/28/2023

5 very positive mentions
3 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/27/2024

7 very positive mentions
11 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

2/26/2024

9 very positive mentions
17 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

3/27/2024

8 very positive mentions
4 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

4/26/2024

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Today's Range

Now: $15.43

$14.90

$15.49

50 Day Range

MA: $19.03

$14.96

$23.35

52 Week Range

Now: $15.43

$14.56

$33.31

Volume

1,122,303 shs

Average Volume

1,179,728 shs

Market Capitalization

$2.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.33

Frequently Asked Questions

What sell-side analysts currently cover shares of Denali Therapeutics?: The following equities research analysts have issued stock ratings on Denali Therapeutics in the last year: B. Riley, Cantor Fitzgerald, Citigroup Inc., HC Wainwright, JPMorgan Chase & Co., Stifel Nicolaus, The Goldman Sachs Group, Inc., TheStreet, UBS Group AG, and Wedbush.
View the latest analyst ratings for DNLI.
What is the current price target for Denali Therapeutics?: 9 Wall Street analysts have set twelve-month price targets for Denali Therapeutics in the last year. Their average twelve-month price target is $41.22, suggesting a possible upside of 167.2%. HC Wainwright has the highest price target set, predicting DNLI will reach $95.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $28.00 for Denali Therapeutics in the next year.
View the latest price targets for DNLI.
What is the current consensus analyst rating for Denali Therapeutics?: Denali Therapeutics currently has 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DNLI will outperform the market and that investors should add to their positions of Denali Therapeutics.
View the latest ratings for DNLI.
What other companies compete with Denali Therapeutics?: Other companies that are similar to Denali Therapeutics include Vericel, Kymera Therapeutics, CG Oncology, Beam Therapeutics and Ginkgo Bioworks. Learn More about companies similar to Denali Therapeutics.
How do I contact Denali Therapeutics' investor relations team?: Denali Therapeutics' physical mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (615) 866-8548 and its investor relations email address is [email protected]. The official website for Denali Therapeutics is www.denalitherapeutics.com. Learn More about contacing Denali Therapeutics investor relations.

Denali Therapeutics - DNLI Stock Price Target and Predictions

Analyst Price Target for DNLI

Current Consensus is Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.96 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Denali Therapeutics?

What is the current price target for Denali Therapeutics?

What is the current consensus analyst rating for Denali Therapeutics?

What other companies compete with Denali Therapeutics?

How do I contact Denali Therapeutics' investor relations team?